Skip to main content

Table 2 Baseline characteristics

From: Differences in presentation of symptoms between women and men with intermittent claudication

 

Group 1(IC)

Group 2 (Control)

Group 3(Follow-up IC)

 

Men

(N = 153)

(46.0%)

Women

(N = 180)

(54.0%)

Men

(N = 1579)

(47.7%)

Women

(N = 1734)

(52.3%)

Men

(N = 37)

(42.1%)

Women

(N = 51)

(58.0%)

Age

Mean (Std.dev.)

76.3(8.1)

77.0(7.8)

69.9(7.3)

70.6(7.6)

78.7(8.12)

77.5(7.96)

ABI

Median (IQR)

0.72(0.19)

0.71(0.29)

1.07(0.14)

1.00(0.10)

0.69 (0.21)

0.71 (0.29)

(p-value)***

(0.438)

(< .001)

(0.74)

Concomittant diseases

N (%)

Diabetes n = 3646

42 (27.5)

32 (17.8)

125 (7.9)

119 (6.9)

9 (25.0)

4 (7.7)

(p-value)**

(0.047)

(.258)

(0.033)

Hypertension

n = 3646

86 (56.2)

97 (53.9)

494(31.3)

592(34.1)

19 (52.8)

31 (59.6)

(p-value)**

(0.740)

(0.082)

(0.662)

Stroke

n = 3646

38 (24.8)

12 (6.7)

103 (6.5)

76 (4.4)

9 (25.0)

3 (5.8)

(p-value)**

(< 0.001)

(0.007)

(0.013)

CAD#

n = 3646

26 (17.0)

8 (4.4)

271 (17.2)

222 (12.8)

6 (16.7)

3 (5.8)

(p-value)**

(< 0.001)

(< 0.001)

(0.151)

Medication use

N (%)

Anti-platelet

therapy, n = 2380

134 (99.3)

151 (96.8)

868 (91.5)

1066 (93.5)

34 (100)

47 (97.9)

(p-value)**

(0.221)

(0.079)

(1.00)

Lipidlowering therapy, n = 2380

53 (39.3)

45 (28.9)

238 (25.1)

214 (18.8)

12 (35.3)

13 (27.1)

(p-value)**

(0.064)

(< 0.001)

(0.472)

ACE-inhib. Betablockers n = 2380

73 (54.7)

82 (52.6)

420 (44.3)

397 (34.8)

25 (73.5)

28 (58.3)

(p-value)**

(0.815)

(< 0.001)

(0.170)

WIQ subscales

WIQ distance*

44.6

36.1

100.0

100.0

34.5

40.3

(p-value)***

(0.121)

 

(0.833)

WIQ speed*

26.1

21.7

89.1

68.5

20.7

23.9

(p-value)***

(0.013)

(< 0.001)

(0.860)

WIQ stairs*

43.8

41.7

100.0

87.5

41.7

37.5

(p-value)***

(0.13)

(< 0.001)

(0.937)

Smoking ever

N (%)

Yes

119 (77.8)

89 (49.4)

968 (61.3)

716 (41.3)

26 (72.2)

29 (55.8)

(p-value) ***

(< 0.001)

(< 0.001)

(0.179)